Dr. Kieran Harkin:

The model was used in Australia to fund hepatitis C treatment and I understand that it worked very well. They said: "We will treat on a population basis. We do not care how many people there are. Roll up as many as you want and we will actually offer the service." It was a successful model but I do not know what the relevant figure is. Having said that, we are saying it is a successful model because it might be, say, €10,000 per head compared with the initial price of €80,000. However, we know that it costs €100 to manufacture the hepatitis C treatment. It depends on where one is coming from. It is a less bad option in some cases.